Kevin Art, MD
Urology · Lexington, KYNPI 1487775797
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,924 of the $3,672 with a category attached, or 79.6%. 34 manufacturers reported payments, led by Neotract Inc. at 28.3% of the total. Reporting peaked in 2019 at $1,835 and has fallen 97.8% since, to $41 in 2025.
Across 118 payments — averaging $31.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Boston Scientific$540
- AbbVie$402
- Pfizer$194
- Intuitive Surgical$166
- Astellas Pharma US Inc$163
- plus $1K from 28 others
What the payments were for
- Travel & lodging$72120%
- Food & beverage$2,92480%
- Entertainment$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 6 | $1,038 |
| Boston Scientific | 12 | $540 |
| AbbVie | 21 | $402 |
| Pfizer | 12 | $194 |
| Intuitive Surgical | 1 | $166 |
| Astellas Pharma US Inc | 8 | $163 |
| Teleflex LLC | 7 | $124 |
| Blue Earth Diagnostics | 6 | $115 |
| Urogen Pharma, Inc. | 5 | $91 |
| Johnson & Johnson(2 entities) | 5 | $82 |
| Medtronic | 1 | $82 |
| Coloplast | 4 | $64 |
| Ambu Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Progenics Pharmaceuticals, Inc. | 2 | $50 |
| Dendreon Pharmaceuticals LLC | 1 | $35 |
| Photocure Inc | 2 | $33 |
| Axonics, Inc. | 2 | $33 |
| Antares Pharma, Inc. | 2 | $31 |
| Civco Medical Instruments | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Tolmar, Inc. | 1 | $28 |
| Provepharm Inc. | 1 | $27 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $27 |
| Myovant Sciences Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Abbott | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| 180 Medical, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Rochester Medical Corporation | 1 | $14 |
| X-spine Systems, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,672 in reported general payments places this provider in the 60th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 169 | $127,375 |
| GemtesaVibegron | 67 | $61,179 |
| Tamsulosin Hcl | 513 | $6,392 |
| Methenamine Hippurate | 74 | $4,627 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 122 | $2,271 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,751 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,412 |
| Estradiol | 15 | $1,365 |
| Trospium Chloride | 21 | $1,342 |
| NitrofurantoinNitrofurantoin Macrocrystal | 33 | $1,044 |
| Solifenacin Succinate | 40 | $999 |
| Oxybutynin Chloride ErOxybutynin Chloride | 48 | $775 |
| Finasteride | 47 | $759 |
| Dutasteride | 22 | $706 |
| Testosterone Cypionate | 16 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $163 | $127,375169 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $51 | $61,17967 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 139 urology providers in Kentucky.
Other urology in Lexington
- Thomas SlabaughLexington$102K
- Patrick HensleyLexington$50K
- Stephen MonnigLexington$18K
- Frances MartinLexington$11K
- Andrew ToddLexington$9K
- Terrence GrimmLexington$9K
- Andrew HarrisLexington$8K
- James AngelLexington$8K
- Justin JohnsonLexington$7K
- Fred HadleyLexington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.